贞芪扶正颗粒联合安罗替尼辅以常规化疗对非小细胞肺癌患者近期疗效及免疫功能的影响

Effect of Zhenqi Fuzheng Granule Combined with Arotinib on Short-term Curative Effect and Immune Function in Patients with Non-small Cell Lung Cancer

目的:探讨贞芪扶正颗粒联合安罗替尼治疗非小细胞肺癌(NSCLC)的疗效与安全性。方法:采用前瞻性随机对照研究,以随机数字表法将2018-11—2020-11本院治疗的178例NSCLC患者分为对照组和观察组,各89例。对照组采用紫杉醇联合顺铂^(+)安罗替尼治疗,观察组在对照组治疗基础上增加贞芪扶正颗粒,两组患者均连续治疗3个疗程。比较两组治疗后近期疗效和治疗前、后血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)、T淋巴细胞亚群CD4^(+)、CD8^(+)比例及KPS评分变化,同时记录不良反应发生情况及半年和一年生存率。结果:治疗后,观察组客观有效率和疾病控制率均高于对照组,而不良反应发生率明显低于对照组(均P<0.05)。与同组治疗前比较,两组患者治疗后血清VEGF、CEA水平均明显降低,观察组更低于对照组;两组治疗后KPS评分均明显增加,观察组更高于对照组(均P<0.05)。与治疗前比较,两组治疗后CD4^(+)比例及CD4^(+)/CD8^(+)比值均升高,观察组较对照组升高更明显;两组CD8^(+)比例均降低,观察组较对照组降低更明显(均P<0.05)。观察组患者一年生存率高于对照组(P<0.05),但两组半年生存率无明显差异(P>0.05)。结论:贞芪扶正颗粒联合安罗替尼辅以常规化疗可有效降低NSCLC患者血清肿瘤标志物水平,可改善患者的健康状况和免疫功能,不良反应少,值得临床推广应用。

Objective:To investigate the efficacy and safety of Zhenqi Fuzheng granule combined with arotinib in the treatment of non-small cell lung cancer(NSCLC).Method:A prospective randomized controlled study was used in this study,178 patients with NSCLC were randomly divided into two groups according to the random number table method,89 cases in each group.Two groups of patients were treated with paclitaxel combined with cisplatin chemotherapy,the control group was treated with arotinib,the observation group was treated with Zhenqi Fuzheng granule combined with arotinib,both groups were treated for 3 courses.The short-term efficacy after treatment,serum levels of VEGF,CEA and KPS score were compared between the two groups before and after treatment,the incidence of adverse reactions and half year and one-year survival rates were recorded.Results:The objective effective rate and disease control rate after treatment of the observation group were higher than those of the control group,and the incidence of adverse reactions was significantly lower than the control group(all P<0.05).Compared with before treatment,the serum levels of VEGF and CEA after treatment of the two groups were significantly decreased,and the observation group was lower than the control group;KPS scores of the two groups were significantly increased,and the observation group was higher than the control group(all P<0.05).Compared with before treatment,the CD4^(+)ratio and CD4^(+)/CD8^(+)were increased after treatment of the two groups,and the observation group was higher;the CD8^(+)ratio was decreased in the two groups,and the observation group was lower(all P<0.05).The one-year survival rate in observation group was higher than control group(P<0.05),but there was no significant difference in the half year survival rate between the two groups(P>0.05).Conclusion:Zhenqi Fuzheng granule combined with arotinib can more significantly reduce the level of serum tumor markers in patients with NSCLC,and has better tumor control effect,fewer adverse reactions.It can also improve the health status and immune function of patients.